Raltegravir

Generic Name: Raltegravir

Brand Names: Isentress

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁FN_₆O_₅

CAS Number: 518048-05-0

Unique Ingredient Identifier: 22VKV8053U

Background: Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.

Indication: For the treatment of HIV-1 infection in conjunction with other antiretrovirals.

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: Post-exposure prophylaxis for occupational exposure to HIV therapy

Clinical Trials

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: raltegravir potassium

First Posted Date: 2006-02-17

Last Posted Date: 2015-09-07

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 352

Registration Number: NCT00293267

Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)

Phase 2

Completed

Conditions: Acquired Immunodeficiency Syndrome
HIV Infections

Interventions: Drug: MK0518
Drug: Placebo

First Posted Date: 2005-03-09

Last Posted Date: 2015-12-04

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 179

Registration Number: NCT00105157

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed

Conditions: HIV Infections

Interventions: Drug: darunavir/ritonavir dosage #1
Drug: TAF w/cobicistat
Drug: TAF w/cobicistat or ritonavir
Drug: tenofovir alafenamide fumarate (TAF)
Drug: elvitegravir/cobicistat
Drug: darunavir/cobicistat
Drug: atazanavir/cobicistat
Drug: lopinavir/ritonavir dosage #1
Drug: atazanavir/ritonavir/tenofovir dosage #1
Drug: lopinavir/ritonavir dosage #2
Drug: indinavir/ritonavir dosage #1
Drug: fosamprenavir/ritonavir
Drug: atazanavir/ritonavir dosage #1
Drug: didanosine delayed release (Videx® EC)
Drug: emtricitabine
Drug: nelfinavir dosage #1
Drug: tipranavir/ritonavir
Drug: etravirine
Drug: darunavir/ritonavir dosage #4
Drug: indinavir/ritonavir dosage #2
Drug: rilpivirine
Drug: ethambutol
Drug: efavirenz
Drug: raltegravir
Drug: dolutegravir
Drug: kanamycin
Drug: nevirapine
Drug: amprenavir
Drug: abacavir
Drug: tenofovir
Drug: maraviroc
Drug: nelfinavir dosage #2
Drug: darunavir/ritonavir dosage #2
Drug: lopinavir/ritonavir dosage #3
Drug: lopinavir/ritonavir dosage #4
Drug: tenofovir/atazanavir/ritonavir dosage #2
Drug: atazanavir/ritonavir dosage #2
Drug: rifampicin
Drug: amikacin
Drug: etonogestrel implant
Drug: darunavir/ritonavir dosage #3
Drug: capreomycin
Drug: ethinyl estradiol
Drug: isoniazid
Drug: moxifloxacin
Drug: levoflaxacin
Drug: pyrazinamide
Drug: ofloxacin
Drug: ethionamide/prothionamide
Drug: terizidone/cycloserine
Drug: para-aminosalicylic acid (PAS)
Drug: high dose INH
Drug: bedaquiline
Drug: clofazamine
Drug: delamanid
Drug: linezolid
Drug: pretomanid

First Posted Date: 2002-08-01

Last Posted Date: 2022-07-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1578

Registration Number: NCT00042289

Locations: 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦
Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸
Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States

and more 59 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy